<article article-type="research-article" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Drug Saf Regul</journal-id><journal-id journal-id-type="iso-abbrev">Front Drug Saf Regul</journal-id><journal-id journal-id-type="pmc-domain-id">4790</journal-id><journal-id journal-id-type="pmc-domain">fdsr</journal-id><journal-id journal-id-type="publisher-id">Front. Drug Saf. Regul.</journal-id><journal-title-group><journal-title>Frontiers in Drug Safety and Regulation</journal-title></journal-title-group><issn pub-type="epub">2674-0869</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12827739</article-id><article-id pub-id-type="pmcid-ver">PMC12827739.1</article-id><article-id pub-id-type="pmcaid">12827739</article-id><article-id pub-id-type="pmcaiid">12827739</article-id><article-id pub-id-type="pmid">41586430</article-id><article-id pub-id-type="doi">10.3389/fdsfr.2025.1736759</article-id><article-id pub-id-type="publisher-id">1736759</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Hepatobiliary adverse drug reactions during treatment with olaparib: an analysis of data from the EudraVigilance reporting system</article-title><alt-title alt-title-type="left-running-head">Velişcu et al.</alt-title><alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fdsfr.2025.1736759" xmlns:xlink="http://www.w3.org/1999/xlink">10.3389/fdsfr.2025.1736759</ext-link>
</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Velişcu</surname><given-names initials="EM">Elena-Mirabela</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="author-notes" rid="fn001">
<sup>†</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/3305816" xmlns:xlink="http://www.w3.org/1999/xlink"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal Analysis</role></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name name-style="western"><surname>Cagnotta</surname><given-names initials="C">Cecilia</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="corresp" rid="c001">*</xref><xref ref-type="author-notes" rid="fn001">
<sup>†</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/3262065" xmlns:xlink="http://www.w3.org/1999/xlink"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal Analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sullo</surname><given-names initials="MG">Maria Giuseppa</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal Analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/">Writing - review and editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Anatriello</surname><given-names initials="A">Antonietta</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2707589" xmlns:xlink="http://www.w3.org/1999/xlink"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal Analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Salvo</surname><given-names initials="F">Francesco</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref><xref ref-type="author-notes" rid="fn002">
<sup>‡</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/515479" xmlns:xlink="http://www.w3.org/1999/xlink"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/">Writing - review and editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Scavone</surname><given-names initials="C">Cristina</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref><xref ref-type="author-notes" rid="fn002">
<sup>‡</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/">Writing - review and editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution>Eu2P Programme, University Bordeaux</institution>, <city>Bordeaux</city>, <country country="FR">France</country>
</aff><aff id="aff2">
<label>2</label>
<institution>Department of Experimental Medicine – University of Campania “Luigi Vanvitelli”</institution>, <city>Naples</city>, <country country="IT">Italy</country>
</aff><aff id="aff3">
<label>3</label>
<institution>Regional Center of Pharmacovigilance and Pharmacoepidemiology of Campania Region</institution>, <city>Naples</city>, <country country="IT">Italy</country>
</aff><aff id="aff4">
<label>4</label>
<institution>University Bordeaux, INSERM, BPH, U1219, Team AHeaD</institution>, <city>Bordeaux</city>, <country country="FR">France</country>
</aff><aff id="aff5">
<label>5</label>
<institution>CHU de Bordeaux, Pôle de Santé Publique, Service de Pharmacologie médicale, Centre Régional de Pharmacovigilance Bordeaux-DROM</institution>, <city>Bordeaux</city>, <country country="FR">France</country>
</aff><aff id="aff6">
<label>6</label>
<institution>Department of Life Science, Health, and Health Professions, Link Campus University</institution>, <city>Rome</city>, <country country="IT">Italy</country>
</aff><author-notes><corresp id="c001">
<label>*</label>Correspondence: Cecilia Cagnotta, <email xlink:href="mailto:cecilia.cagnotta@unicampania.it" xmlns:xlink="http://www.w3.org/1999/xlink">cecilia.cagnotta@unicampania.it</email>
</corresp><fn fn-type="equal" id="fn001"><label>†</label><p>These authors have contributed equally to this work</p></fn><fn fn-type="equal" id="fn002"><label>‡</label><p>These authors have contributed equally to this work and share senior authorship</p></fn></author-notes><pub-date date-type="pub" iso-8601-date="2026-01-09" publication-format="electronic"><day>09</day><month>1</month><year>2026</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>5</volume><issue-id pub-id-type="pmc-issue-id">497030</issue-id><elocation-id>1736759</elocation-id><history><date date-type="received"><day>31</day><month>10</month><year>2025</year></date><date date-type="rev-recd"><day>17</day><month>12</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>24</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-26 15:25:12.620"><day>26</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>Copyright © 2026 Velişcu, Cagnotta, Sullo, Anatriello, Salvo and Scavone.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder>Velişcu, Cagnotta, Sullo, Anatriello, Salvo and Scavone</copyright-holder><license><ali:license_ref content-type="ccbylicense" specific-use="textmining" start_date="2026-01-09" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="fdsfr-05-1736759.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract><sec><title>Background</title><p>olaparib is a Poly ADP-Ribose Polymerase inhibitor approved for the treatment of BRCA-mutated tumors, and has been associated with hepatotoxicity, as highlighted by the Pharmacovigilance Risk Assessment Committee.</p></sec><sec><title>Objectives and methods</title><p>to describe Drug-Induced Liver Injury (DILI) cases related to olaparib stratifying them by liver damage origin in “cholestatic”, “cytolytic”, “mixed”, “liver related investigation” and “not specified” cases, by analyzing data from EudraVigilance (EV) database.</p></sec><sec><title>Results</title><p>344 Individual Case Safety Reports (ICSRs) reporting olaparib-induced liver injury cases were retrieved from the EV. They referred more frequently to female patients belonging to the age group 18–64 years. The majority of ICSRs (66.0%) reported serious Adverse events (AEs), classified as “Other Medically Important Condition”, while 23 ICSRs reported fatal AEs. Among the 344 DILI cases, 19.5% were classified as “cytolytic”, 3.5% as “cholestatic” and 1.5% as “mixed” origin. Most DILI cases were temporally associated with “liver-related investigations” (39.8%) and 15.1% were classified as “not specified”. A further 20.6% of cases involved PTs related to liver neoplasms (benign or malignant).</p></sec><sec><title>Conclusion</title><p>Further pharmacovigilance studies are needed to evaluate the hepatic safety profile of olaparib. Investigating the pathophysiological mechanisms underlying olaparib-induced liver injury could offer clinicians valuable insights for its prevention and management.</p></sec></abstract><kwd-group><kwd>adverse events</kwd><kwd>DILI cases</kwd><kwd>EudraVigilance</kwd><kwd>olaparib</kwd><kwd>safety profile</kwd></kwd-group><funding-group><funding-statement>The author(s) declared that financial support was not received for this work and/or its publication.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="4"/><equation-count count="0"/><ref-count count="40"/><page-count count="11"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Advanced Methods in Pharmacovigilance and Pharmacoepidemiology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><label>1</label><title>Introduction</title><p>Germline mutations in the Breast Cancer gene-1 (BRCA1) and Breast Cancer gene-2 (BRCA2) are identified as significant risk factors for the development of solid tumors, including ovarian, breast, prostate and pancreatic cancers (<xref ref-type="bibr" rid="B18">Golan et al., 2019</xref>; <xref ref-type="bibr" rid="B6">Boussios et al., 2022</xref>). BRCA genes play a crucial role in DNA damage response because they encode proteins taking part in the repair process of double-strand DNA breaks by homologous recombination (<xref ref-type="bibr" rid="B35">Tobalina et al., 2021</xref>). The identification of these mutations has improved the development of target therapy based on poly-ADP ribose polymerase (PARP) inhibitors. PARP is a protein that supports damaged cells to repair themselves. Thus, PARP inhibitors, which currently include olaparib, rucaparib, niraparib and talazoparib, stop the PARP from doing its repair work in cancer cells leading to cancer cells’ death (<xref ref-type="bibr" rid="B18">Golan et al., 2019</xref>; <xref ref-type="bibr" rid="B6">Boussios et al., 2022</xref>).</p><p>Olaparib was the first PARP inhibitor to be approved in 2014 by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the oral treatment of BRCA-mutated advanced ovarian cancer in patients who had previously received three or more lines of chemotherapy (<xref ref-type="bibr" rid="B20">Kim et al., 2015</xref>). Throughout the years, the therapeutic indications of the drug were extended for the treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer after the first-line platinum-based chemotherapy, HER2-negative metastatic breast cancer, BRCA-mutated metastatic castration-resistant prostate cancer, pancreatic and endometrial cancer (<xref ref-type="bibr" rid="B14">Food and Drug Administration, 2024a</xref>; <xref ref-type="bibr" rid="B15">Food and Drug Administration, 2024b</xref>; <xref ref-type="bibr" rid="B16">Food and Drug Administration, 2024c</xref>; <xref ref-type="bibr" rid="B13">Fallah et al., 2024</xref>). Olaparib acts as a competitive inhibitor of NAD+ in the catalytic site of PARP1 and PARP2, which are involved in the repair process of DNA single-strand breaks (SSBs). Thus, olaparib leads to the accumulation of unrepaired SSBs and to the formation of dangerous double-strand breaks, which can be quickly repaired in healthy cells. In tumor cells, lacking in homologous recombination repair, the accumulation of unrepaired DNA damage is fatal, and the obstruction of replication forks leads to replication arrest. These multiple mechanisms explain the reason why tumor cells show sensitivity to olaparib and other PARP inhibitors (<xref ref-type="bibr" rid="B5">Bochum et al., 2018</xref>; <xref ref-type="bibr" rid="B28">Robson et al., 2017</xref>).</p><p>The results of both 5- and 7-year follow up analysis of phase III SOLO1 trial (<xref ref-type="bibr" rid="B3">Banerjee et al., 2021</xref>; <xref ref-type="bibr" rid="B8">DiSilvestro et al., 2023</xref>) and the evidence of a meta-analysis carried out by <xref ref-type="bibr" rid="B19">Guo et al. (2018)</xref> reported also the occurrence of neutropenia and thrombocytopenia. However, following the meeting held by the Pharmacovigilance Risk Assessment Committee (PRAC) on 31 July 2023 (<xref ref-type="bibr" rid="B12">European Medicines Agency, 2025</xref>), the EMA informed healthcare professionals (HCPs) about cases of hepatocellular damage and hepatitis occurring during the treatment with olaparib and provided special warnings and precautions for patients showing clinical symptoms or signs of hepatotoxicity or suspected Drug-Induced Liver Injury (DILI).</p><p>Generally, liver injury is identified as a common consequence of the administration of a variety of drugs, and in most cases, it requires the treatment discontinuation. When DILI is dose related, it is defined as intrinsic, direct or predictable, while when it is not dose-dependent, it can be defined as idiosyncratic (<xref ref-type="bibr" rid="B32">Scavone et al., 2020</xref>; <xref ref-type="bibr" rid="B33">Sow et al., 2021</xref>). Cytolytic liver damage represents a form of liver inflammation and injury characterized by the destruction of hepatocytes which is typically indicated by an increase in liver enzymes of five times the upper limit of normal, appearing within 90 days of drug initiation (<xref ref-type="bibr" rid="B1">Aithal et al., 2011</xref>; <xref ref-type="bibr" rid="B17">Garcia-Cortes et al., 2020</xref>). This liver damage can result from various causes, including medications. As reported by <xref ref-type="bibr" rid="B40">Zhu et al. (2024)</xref>, DILI can be immune-mediated, resulting from the hepatic metabolism of the culprit drugs leading to reactive metabolites binding to hepatocytes and leading to autoantibodies reacting with liver-specific antigens as well as direct toxic effect on hepatocytes. Indeed, reactive metabolites may lead to hepatic damage by different mechanisms, such as oxidative stress, inflammation, cellular death due to apoptosis or necrosis and mitochondrial membrane alteration and organ dysfunction (<xref ref-type="bibr" rid="B4">Björnsson and Björnsson, 2022</xref>). Moreover, in some people genetically predisposed, stress can trigger innate immune responses which cause a co-stimulation for an adaptive immune response (<xref ref-type="bibr" rid="B22">Luo et al., 2017</xref>). Data from clinical trials revealed that almost 4% of patients receiving olaparib experienced abnormalities in routine liver tests (<xref ref-type="bibr" rid="B29">Rucaparib, 2017</xref>). Abnormal liver values, such as increasing ALT concentrations, have been reported also during clinical trials with rucaparib, another PARP inhibitor. On the other hand, no cases of hepatitis with jaundice or liver failure have been described for this drug. This means that rucaparib can lead to increased blood concentration of liver enzymes, but it has not been related to significant hepatotoxicity (<xref ref-type="bibr" rid="B26">Niraparib, 2017</xref>). The same is true for niraparib (<xref ref-type="bibr" rid="B39">Yang et al., 2021</xref>).</p><p>Considering that olaparib was the first PARP inhibitor to be approved being used in clinical practice and given the relevance of hepatic AEs highlighted by the PRAC, we aimed to describe cases of olaparib-induced liver injury using data from the European spontaneous reporting system (EudraVigilance) and to stratify these cases according to the liver damage origin as cytolytic, cholestatic, mixed, not specified, and liver related investigation.</p></sec><sec id="s2" sec-type="methods"><label>2</label><title>Methods</title><sec id="s2-1"><label>2.1</label><title>Data source</title><p>EudraVigilance (EV) is the European pharmacovigilance database that collects Individual Case Safety Reports (ICSRs) reporting AEs related to vaccines and drugs which are authorized within the European Economic Area (EEA). The EMA manages the database on behalf of the EU drug regulatory network. EV is publicly accessible at <ext-link ext-link-type="uri" xlink:href="https://www.adrreports.eu/en/search.html" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.adrreports.eu/en/search.html</ext-link>.</p><p>ICSRs reporting olaparing as suspected drug collected in EV from 2014 until 25-July-2025 were considered. ICSRs were downloaded in excel files that were combined and analyzed for the purposes of this study.</p><p>In EV, AEs are coded as preferred terms (PTs) using event-related information according to the Medical Dictionary for Regulatory Activities (MedDRA). MedDRA is a hierarchical dictionary that is used to code symptoms, signs, and diagnoses medical and surgical procedures, investigations, medical/social history and therapeutic indications. The MedDRA’s structure develops on multiple levels, from the Low-Level Terms (LLT) level to the System Organ Class (SOC) level. Each level provides gradually broader categories. Each PT is linked at least with a High-Level Term (HLT), a High-Level Group Term (HLGT) and a System Organ Class (SOC) level. For example, the SOC “Hepatobiliary disorders’’ contains “hepatic and hepatobiliary disorders’’ HLGT, which include “cholestasis and jaundice” as HLT, “hepatitis cholestatic” as PT and “acute cholestatic hepatitis” as LLT.</p><p>In addition, Standardised MedDRA Queries (SMQs) were used to facilitate the retrieval of ICSRs related to a medical condition that can be shared by different system organs, or that can be coded using different PTs. Regarding any medical condition of interest, SMQs contain terms related to its signs, symptoms, diagnoses, syndromes, physical findings, laboratory and other physiological test data (<xref ref-type="bibr" rid="B7">Brown, 2003</xref>; <xref ref-type="bibr" rid="B31">Sakaeda et al., 2013</xref>; <xref ref-type="bibr" rid="B24">Mozzicato, 2007</xref>). For example, two PTs of two different SOCs, such as “hepatitis” (belonging to the SOC “Hepatobiliary disorders”) and “transaminases increased” (belonging to the SOC “Investigations”), can be grouped in the same SMQ “Hepatic disorders”. Each SMQ contains both narrow and broad search terms to describe a medical condition in various forms. Narrow terms are those that are highly likely to represent the condition of interest, while broad terms are less specific to the condition and require additional terms to qualify a case for the SMQ. In addition, some SMQs have a hierarchical structure and contain subordinate SMQs. For example, the SMQ “Liver-related coagulation and bleeding disturbances” is a sub-SMQ of Drug related hepatic disorders–comprehensive search (SMQ), which is itself a sub-SMQ of Hepatic disorder (SMQ). The SMQ on hepatic disorders includes events that can be drug-related or not. The hierarchy structure of this SMQ consists of 13 sub-SMQs (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref ref-type="bibr" rid="B23">Meddra, 2025</xref>).</p><fig id="F1" orientation="portrait" position="float"><label>FIGURE 1</label><caption><p>Hierarchy structure of the SMQ related to Hepatic disorders according to MedDRA. Reproduced from Introductory Guide for Standardised MedDRA Queries (SMQs), Version 25.1. © ICH. The material is used in accordance with the public copyright permission granted by ICH. No endorsement or sponsorship by ICH is implied.</p></caption><graphic orientation="portrait" position="float" xlink:href="fdsfr-05-1736759-g001.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"><alt-text content-type="machine-generated">Flowchart illustrating the classification of hepatic disorders under the SMQ system. Top level: Hepatic disorders. Second level: Drug-related hepatic disorders; Congenital, familial, neonatal, and genetic disorders; Liver infections; Alcohol-related hepatic disorders; Pregnancy-related hepatic disorders. Third level under Drug-related hepatic disorders: Severe events only, Liver-related investigations, signs and symptoms, Cholestasis and jaundice of hepatic origin, Liver-related coagulation and bleeding disturbances. Fourth level under Liver neoplasms: Liver malignant tumors, Liver tumors of unspecified malignancy. Additional category: Hepatic failure, fibrosis, and cirrhosis.</alt-text></graphic></fig></sec><sec id="s2-2"><label>2.2</label><title>Case definition</title><p>To select DILI cases related to olaparib, we considered the narrow terms of the SMQs “Drug related hepatic disorders–comprehensive search” (20000006), excluding the SMQs that do not contain PTs suggestive of drug-related liver injury (“Congenital, familial, neonatal and genetic disorders of the liver”, “Liver infections”, “Hepatic disorders specifically reported as alcohol-related”, “Pregnancy-related hepatic disorders”). We retrieved the ICSRs reporting olaparib as suspected drug and narrow PTs of the SMQ 20000006, collected in EV from 2014 until 25-July-2025, using the line-listing function. We identified potential duplicates by comparing case IDs and removed them from the dataset.</p><p>A case of DILI was defined as an ICSR reporting olaparib as suspected drug, and at least one narrow PT related to the SMQs “Drug related hepatic disorders–comprehensive search” (20000006). Moreover, cases of DILI were stratified by liver damage origin (<xref ref-type="sec" rid="s12">Supplementary Table S1</xref>):<list list-type="order"><list-item><p>Cytolytic: ICSRs reporting at least one PT belonging to the SMQs “Drug related hepatic disorders–severe events only” (20000007) and suggesting hepatocyte cytolysis.</p></list-item><list-item><p>Cholestatic: ICSRs reporting at least one PT belonging to the SMQs “Cholestasis and jaundice of hepatic origin” (20000009) and suggesting an alteration of the normal flow of bile from the liver to the intestine.</p></list-item><list-item><p>Mixed: ICSRs reporting both PTs of cytolytic origin and PTs of cholestatic origin.</p></list-item><list-item><p>Not specified: ICSRs reporting PTs not specifically attributable to cytolytic or cholestatic origin (i.e., PTs belonging to both the SMQs “Drug related hepatic disorders–severe events only” and “Cholestasis and jaundice of hepatic origin”).</p></list-item><list-item><p>Liver related investigation: ICSRs reporting only PTs belonging to the sub-SMQs “Liver related investigations, signs and symptoms” (20000008) or “Liver related coagulation and bleeding disturbances” (20000015).</p></list-item><list-item><p>Liver neoplasm or nonspecific signs: ICSRs reporting at least one PT related to liver neoplasm (benign or malignant) or only PTs related to nonspecific signs and symptoms.</p></list-item></list>
</p><p>The screening of cases and the final selection of DILI cases was carried out by a team made up of pharmacists and pharmacologists, including a clinician expert in pharmacovigilance.</p></sec><sec id="s2-3"><label>2.3</label><title>Data analyses</title><p>All retrieved ICSRs were analyzed in terms of patients’ age group and gender, primary source country for regulatory purposes (EEA or non-EEA), reporter type (HCP or non-HCP), distribution of all AEs reported in each ICSR by SOC, type of DILIs, seriousness and outcome degrees. Specifically, a case was defined as “serious’’ when it resulted in death, in persistent or significant disability or incapacity, when it caused or prolonged hospitalization, when it was life-threatening, it determined a congenital anomaly/birth defect, or it was classified under other medically important conditions (<xref ref-type="bibr" rid="B11">European Medicines Agency, 2024</xref>). The outcome was instead classified as “Fatal”, “Not Recovered/Not Resolved’’, “Recovered/Resolved with sequelae”, “Recovered/Resolved’’, “Recovering/Resolving’’ and “Unknown’’. The outcome with the lower level of resolution was chosen for classification whether an ICSR reported two or more PTs of interest with different outcomes (<xref ref-type="bibr" rid="B10">EMA, 2023</xref>). Two independent reviewers (EMV and CC) analyzed excel files and performed the process for phenotype assignment <italic toggle="yes">w</italic>th the support of the multidisciplinary team previously mentioned. Any discrepancy was resolved through discussion.2.4. Ethical standards.</p><p>Safety data extracted from the spontaneous reporting system comply with ethical standards and are anonymous. Therefore, no ethical measures were enforced further.</p></sec></sec><sec id="s3" sec-type="results"><label>3</label><title>Results</title><sec id="s3-1"><label>3.1</label><title>Main characteristics of DILI cases</title><p>During the study period, 344 ICSRs reporting olaparib-induced liver injury cases were retrieved from the EV (<xref ref-type="table" rid="T1">Table 1</xref>). DILI cases referred more frequently to patients belonging to the age group 18–64 years (44.5%) and to the female gender (82%). The primary source country was mostly non-European Economic Area (EEA) (64.8%) and the primary source qualification was mainly represented by HCPs (84.0%). Regarding the seriousness degree, the majority of ICSRs reported AEs that were classified as “Other Medically Important Condition’’ (41%) and “Non serious” (34.0%), while the outcome was mainly reported as unknown (54.4%) and “Recovered/Resolved” (16.9%). Overall, there were 23 ICSRs related to fatal AEs (please see <xref ref-type="sec" rid="s3-3">section 3.3</xref> Fatal cases).</p><table-wrap id="T1" orientation="portrait" position="float"><label>TABLE 1</label><caption><p>Demographic and clinical characteristics of Drug-Induced Liver Injury (DILI) cases with olaparib as suspected drug and retrieved from the EudraVigilance databases from 2014 until 22- July −2025.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" colspan="1" rowspan="1">ICSRs (N = 344)</th><th align="left" colspan="1" rowspan="1">​</th><th align="left" colspan="1" rowspan="1">n (%)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="4">Age group</td><td align="left" colspan="1" rowspan="1">18–64 Years</td><td align="left" colspan="1" rowspan="1">153 (44.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">65–85 Years</td><td align="left" colspan="1" rowspan="1">75 (21.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">More than 85 Years</td><td align="left" colspan="1" rowspan="1">2 (0.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Not specified</td><td align="left" colspan="1" rowspan="1">114 (33.1)</td></tr><tr><td align="left" colspan="1" rowspan="3">Sex</td><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">282 (82.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">57 (16.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">5 (1.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Report type</td><td align="left" colspan="1" rowspan="1">Spontaneous</td><td align="left" colspan="1" rowspan="1">344 (100.0)</td></tr><tr><td align="left" colspan="1" rowspan="2">Source qualification</td><td align="left" colspan="1" rowspan="1">Non-healthcare professional</td><td align="left" colspan="1" rowspan="1">55 (16.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Healthcare professional</td><td align="left" colspan="1" rowspan="1">289 (84.0)</td></tr><tr><td align="left" colspan="1" rowspan="2">Source country</td><td align="left" colspan="1" rowspan="1">Non-european economic area</td><td align="left" colspan="1" rowspan="1">223 (64.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">European economic area</td><td align="left" colspan="1" rowspan="1">121 (35.2)</td></tr><tr><td align="left" colspan="1" rowspan="6">Seriousness</td><td align="left" colspan="1" rowspan="1">Non serious</td><td align="left" colspan="1" rowspan="1">117 (34.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Other medically important condition</td><td align="left" colspan="1" rowspan="1">141 (41.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Caused/Prolonged hospitalisation</td><td align="left" colspan="1" rowspan="1">52 (15.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Results in death</td><td align="left" colspan="1" rowspan="1">23 (6.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Life threatening</td><td align="left" colspan="1" rowspan="1">9 (2.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Disabling</td><td align="left" colspan="1" rowspan="1">2 (0.6)</td></tr><tr><td align="left" colspan="1" rowspan="6">Outcome</td><td align="left" colspan="1" rowspan="1">Not reported</td><td align="left" colspan="1" rowspan="1">187 (54.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Recovered/Resolved</td><td align="left" colspan="1" rowspan="1">58 (16.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Recovering/Resolving</td><td align="left" colspan="1" rowspan="1">43 (12.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Not recovered/Not resolved</td><td align="left" colspan="1" rowspan="1">33 (9.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Fatal</td><td align="left" colspan="1" rowspan="1">23 (6.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Recovered/Resolved with sequelae</td><td align="left" colspan="1" rowspan="1">0</td></tr></tbody></table><table-wrap-foot><fn><p>NA, not available.</p></fn></table-wrap-foot></table-wrap><p>Overall, the retrieved ICSRs covered 439 PTs, which were mostly related to the SOCs “Hepatobiliary disorders” (51.0%), “Investigations” (31.2%), “Gastrointestinal disorders” (14.6%), “Neoplasm benign, malignant and unspecified (incl cysts and polyps)” (2.5%), “Nervous system disorders” (0.5%), “Blood and lymphatic system disorders” (0.2%) (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p><fig id="F2" orientation="portrait" position="float"><label>FIGURE 2</label><caption><p>Distribution of AEs included in the Drug-Induced Liver Injury (DILI) cases reporting olaparib as suspected drug by System Organ Classes (SOCs).</p></caption><graphic orientation="portrait" position="float" xlink:href="fdsfr-05-1736759-g002.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"><alt-text content-type="machine-generated">Bar chart depicting the number of suspected adverse drug reactions (ADRs) across various system organ classes (SOCs). Hepatobiliary disorders lead with 224 ADRs, followed by Investigations with 137, Gastrointestinal disorders with 64, Neoplasms with 11, Nervous system disorders with 2, and Blood and lymphatic system disorders with 1.</alt-text></graphic></fig></sec><sec id="s3-2"><label>3.2</label><title>Stratification of DILI cases by liver damage origin</title><p>Among the 344 DILI cases, 67 (19.5%) were classified as “cytolytic”, 12 (3.5%) as “cholestatic”, and 5 (1.5%) as “mixed” origin, as the corresponding ICSRs included PTs of both cytolytic and cholestatic type. Most DILI cases were temporally associated with “liver-related investigations” (39.8%) and 15.1% were classified as “not specified”, as the reported PTs were not specifically attributable to cytolytic or cholestatic origin. A further 20.6% of cases involved PTs related to liver neoplasms (benign or malignant) or only PTs related to non-specific signs and symptoms (<xref ref-type="table" rid="T2">Table 2</xref>).</p><table-wrap id="T2" orientation="portrait" position="float"><label>TABLE 2</label><caption><p>Demographic and clinical characteristics of Drug-Induced Liver Injury (DILI) cases by liver damage origin with olaparib as suspected drug and retrieved from the EudraVigilance databases from 2014 until 22- July −2025.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" colspan="1" rowspan="1">Liver damage origin</th><th align="center" colspan="1" rowspan="1">Cytolytic<xref ref-type="table-fn" rid="Tfn1">
<sup>a</sup>
</xref> (19.5%)</th><th align="center" colspan="1" rowspan="1">Cholestatic<xref ref-type="table-fn" rid="Tfn2">
<sup>b</sup>
</xref> (3.5%)<break/>
</th><th align="center" colspan="1" rowspan="1">Mixed<xref ref-type="table-fn" rid="Tfn3">
<sup>c</sup>
</xref> (1.5%)<break/>
</th><th align="center" colspan="1" rowspan="1">Not specified<xref ref-type="table-fn" rid="Tfn4">
<sup>d</sup>
</xref> (15.1%)<break/>
</th><th align="center" colspan="1" rowspan="1">Liver related investigation<xref ref-type="table-fn" rid="Tfn5">
<sup>e</sup>
</xref> (39.8%)<break/>
</th><th align="center" colspan="1" rowspan="1">Liver neoplasm or nonspecific signs<xref ref-type="table-fn" rid="Tfn6">
<sup>f</sup>
</xref> (20.6%)<break/>
</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">ICSRs n (%)</td><td align="left" colspan="1" rowspan="1">67 (100)</td><td align="left" colspan="1" rowspan="1">12 (100)</td><td align="left" colspan="1" rowspan="1">5 (100)</td><td align="left" colspan="1" rowspan="1">52 (100)</td><td align="left" colspan="1" rowspan="1">137 (100)</td><td align="left" colspan="1" rowspan="1">71 (100)</td></tr><tr><td align="left" colspan="7" rowspan="1">Age group</td></tr><tr><td align="left" colspan="1" rowspan="1">18–64 Years</td><td align="left" colspan="1" rowspan="1">26 (40.0)</td><td align="left" colspan="1" rowspan="1">7 (58.3)</td><td align="left" colspan="1" rowspan="1">3 (60.0)</td><td align="left" colspan="1" rowspan="1">28 (51.9)</td><td align="left" colspan="1" rowspan="1">62 (45.3)</td><td align="left" colspan="1" rowspan="1">27 (38.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">65–85 Years</td><td align="left" colspan="1" rowspan="1">16 (24.6)</td><td align="left" colspan="1" rowspan="1">3 (25.0)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">12 (22.2)</td><td align="left" colspan="1" rowspan="1">27 (19.7)</td><td align="left" colspan="1" rowspan="1">17 (23.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Not specified</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">2 (1.5)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">More than 85 Years</td><td align="left" colspan="1" rowspan="1">23 (35.4)</td><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1">2 (40.0)</td><td align="left" colspan="1" rowspan="1">14 (25.9)</td><td align="left" colspan="1" rowspan="1">46 (33.6)</td><td align="left" colspan="1" rowspan="1">27 (38.0)</td></tr><tr><td align="left" colspan="7" rowspan="1">Sex</td></tr><tr><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">52 (80.0)</td><td align="left" colspan="1" rowspan="1">8 (66.7)</td><td align="left" colspan="1" rowspan="1">5 (100.0)</td><td align="left" colspan="1" rowspan="1">44 (81.5)</td><td align="left" colspan="1" rowspan="1">108 (78.8)</td><td align="left" colspan="1" rowspan="1">65 (91.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">13 (20.0)</td><td align="left" colspan="1" rowspan="1">3 (25.0)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">8 (14.8)</td><td align="left" colspan="1" rowspan="1">27 (19.7)</td><td align="left" colspan="1" rowspan="1">6 (8.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">1 (8.3)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">2 (3.7)</td><td align="left" colspan="1" rowspan="1">2 (1.5)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td></tr><tr><td align="left" colspan="7" rowspan="1">Report_type</td></tr><tr><td align="left" colspan="1" rowspan="1">Spontaneous</td><td align="left" colspan="1" rowspan="1">65 (100.0)</td><td align="left" colspan="1" rowspan="1">12 (100.0)</td><td align="left" colspan="1" rowspan="1">5 (100.0)</td><td align="left" colspan="1" rowspan="1">54 (100.0)</td><td align="left" colspan="1" rowspan="1">137 (100.0)</td><td align="left" colspan="1" rowspan="1">71 (100.0)</td></tr><tr><td align="left" colspan="7" rowspan="1">Source_qualification</td></tr><tr><td align="left" colspan="1" rowspan="1">Non healthcare professional</td><td align="left" colspan="1" rowspan="1">8 (12.3)</td><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">4 (7.4)</td><td align="left" colspan="1" rowspan="1">12 (8.8)</td><td align="left" colspan="1" rowspan="1">29 (40.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Healthcare professional</td><td align="left" colspan="1" rowspan="1">57 (87.7)</td><td align="left" colspan="1" rowspan="1">10 (83.3)</td><td align="left" colspan="1" rowspan="1">5 (100.0)</td><td align="left" colspan="1" rowspan="1">50 (92.6)</td><td align="left" colspan="1" rowspan="1">125 (91.2)</td><td align="left" colspan="1" rowspan="1">42 (59.2)</td></tr><tr><td align="left" colspan="7" rowspan="1">Source_country</td></tr><tr><td align="left" colspan="1" rowspan="1">Non european economic area</td><td align="left" colspan="1" rowspan="1">42 (64.6)</td><td align="left" colspan="1" rowspan="1">6 (50.0)</td><td align="left" colspan="1" rowspan="1">3 (60.0)</td><td align="left" colspan="1" rowspan="1">34 (63.0)</td><td align="left" colspan="1" rowspan="1">84 (61.3)</td><td align="left" colspan="1" rowspan="1">54 (76.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">European economic area</td><td align="left" colspan="1" rowspan="1">23 (35.4)</td><td align="left" colspan="1" rowspan="1">6 (50.0)</td><td align="left" colspan="1" rowspan="1">2 (40.0)</td><td align="left" colspan="1" rowspan="1">20 (37.0)</td><td align="left" colspan="1" rowspan="1">53 (38.7)</td><td align="left" colspan="1" rowspan="1">17 (23.9)</td></tr><tr><td align="left" colspan="7" rowspan="1">Seriousness</td></tr><tr><td align="left" colspan="1" rowspan="1">Non serious</td><td align="left" colspan="1" rowspan="1">8 (12.0)</td><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">10 (19.2)</td><td align="left" colspan="1" rowspan="1">83 (60.6)</td><td align="left" colspan="1" rowspan="1">14 (19.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Other medically important condition</td><td align="left" colspan="1" rowspan="1">23 (34.3)</td><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1">1 (20.0)</td><td align="left" colspan="1" rowspan="1">34 (65.4)</td><td align="left" colspan="1" rowspan="1">43 (31.4)</td><td align="left" colspan="1" rowspan="1">38 (53.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Caused/Prolonged hospitalisation</td><td align="left" colspan="1" rowspan="1">20 (29.8)</td><td align="left" colspan="1" rowspan="1">5 (41.7)</td><td align="left" colspan="1" rowspan="1">4 (80.0)</td><td align="left" colspan="1" rowspan="1">7 (13.5)</td><td align="left" colspan="1" rowspan="1">6 (4.4)</td><td align="left" colspan="1" rowspan="1">10 (14.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Results in death</td><td align="left" colspan="1" rowspan="1">12 (17.9)</td><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">1 (1.9)</td><td align="left" colspan="1" rowspan="1">1 (0.7)</td><td align="left" colspan="1" rowspan="1">7 (9.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Life threatening</td><td align="left" colspan="1" rowspan="1">3 (4.6)</td><td align="left" colspan="1" rowspan="1">1 (8.3)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">4 (2.9)</td><td align="left" colspan="1" rowspan="1">1 (1.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Disabling</td><td align="left" colspan="1" rowspan="1">1 (1.5)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">1 (1.4)</td></tr><tr><td align="left" colspan="7" rowspan="1">Outcome</td></tr><tr><td align="left" colspan="1" rowspan="1">Not reported</td><td align="left" colspan="1" rowspan="1">29 (43.3)</td><td align="left" colspan="1" rowspan="1">6 (50.0)</td><td align="left" colspan="1" rowspan="1">1 (20.0)</td><td align="left" colspan="1" rowspan="1">26 (50.0)</td><td align="left" colspan="1" rowspan="1">72 (52.6)</td><td align="left" colspan="1" rowspan="1">54 (76.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Not recovered/Not resolved</td><td align="left" colspan="1" rowspan="1">7 (10.8)</td><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1">1 (20.0)</td><td align="left" colspan="1" rowspan="1">6 (11.1)</td><td align="left" colspan="1" rowspan="1">12 (8.8)</td><td align="left" colspan="1" rowspan="1">5 (7.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Recovered/Resolved</td><td align="left" colspan="1" rowspan="1">13 (20.0)</td><td align="left" colspan="1" rowspan="1">1 (8.3)</td><td align="left" colspan="1" rowspan="1">1 (20.0)</td><td align="left" colspan="1" rowspan="1">6 (11.1)</td><td align="left" colspan="1" rowspan="1">34 (24.8)</td><td align="left" colspan="1" rowspan="1">4 (5.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Recovering/Resolving</td><td align="left" colspan="1" rowspan="1">7 (10.8)</td><td align="left" colspan="1" rowspan="1">1 (8.3)</td><td align="left" colspan="1" rowspan="1">2 (40.0)</td><td align="left" colspan="1" rowspan="1">13 (24.1)</td><td align="left" colspan="1" rowspan="1">18 (13.1)</td><td align="left" colspan="1" rowspan="1">1 (1.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Fatal</td><td align="left" colspan="1" rowspan="1">12 (17.9)</td><td align="left" colspan="1" rowspan="1">2 (16.7)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">1 (1.9)</td><td align="left" colspan="1" rowspan="1">1 (0.7)</td><td align="left" colspan="1" rowspan="1">7 (9.9)</td></tr></tbody></table><table-wrap-foot><fn id="Tfn1"><label>
<sup>a</sup>
</label><p>Cytolytic: ICSRs, reporting at least one PT, belonging to the SMQs “Drug related hepatic disorders–severe events only” (20000007) and suggesting hepatocyte cytolysis.</p></fn><fn id="Tfn2"><label>
<sup>b</sup>
</label><p>Cholestatic: ICSRs, reporting at least one PT, belonging to the SMQs “Cholestasis and jaundice of hepatic origin” (20000009) and suggesting an alteration of the normal flow of bile from the liver to the intestine.</p></fn><fn id="Tfn3"><label>
<sup>c</sup>
</label><p>Mixed: ICSRs, reporting both PTs, of cytolytic origin and PTs, of cholestatic origin.</p></fn><fn id="Tfn4"><label>
<sup>d</sup>
</label><p>Not specified: ICSRs, reporting PTs, not specifically attributable to cytolytic or cholestatic origin (i.e., PTs, belonging to both the SMQs “Drug related hepatic disorders–severe events only” and “Cholestasis and jaundice of hepatic origin”).</p></fn><fn id="Tfn5"><label>
<sup>e</sup>
</label><p>Liver related investigation: ICSRs, reporting only PTs, belonging to the sub-SMQs “Liver related investigations, signs and symptoms” (20000008) or “Liver related coagulation and bleeding disturbances” (20000015).</p></fn><fn id="Tfn6"><label>
<sup>f</sup>
</label><p>Liver neoplasm or nonspecific signs: ICSRs, reporting at least one PT, related to liver neoplasm (benign or malignant) or only PTs, related to nonspecific signs and symptoms.</p></fn><fn><p>NA, not available.</p></fn></table-wrap-foot></table-wrap><p>Also stratifying by the origin of liver damage, DILI cases referred more frequently to patients belonging to the age group 18–64 years and to the female gender. For each category, the primary source country for regulatory purposes was mostly non-EEA and more than 50% of ICSRs were reported by HCPs. Regarding the seriousness degree, for each category the majority of ICSRs were classified as serious (88.0% for “cytolytic” cases, 83.3% for “cholestatic” cases, 100.0% for “mixed” cases, 80.8% for “not specified”cases and 80.3% for “liver neoplasm or nonspecific signs” cases). Cases classified as “liver-related investigations” were mostly reported as “Non serious” (60.6%). In addition, the outcome was mainly reported as unknown for all categories, while fatal cases were related only to cytolytic, cholestatic and liver neoplasm or nonspecific signs cases (<xref ref-type="table" rid="T2">Table 2</xref>).</p><p>In cases of cytolytic origin, the most reported PTs were hepatic failure (32.3%), hepatic cytolysis (12.3%) and hepatitis (9.2%), while for cases of cholestatic origin, jaundice (25.0%), cholestasis (25.0%) and jaundice cholestatic (25.0%) were the most reported PTs. Mixed cases, which are ICSRs reporting both PTs of cytolytic and cholestatic origins, mainly reported hepatic cytolysis, hepatitis cholestatic and jaundice as PTs. In cases of not specified origin, liver disorder, drug-induced liver injury, hepatotoxicity and liver injury prevailed. Cases temporally associated with liver investigations most frequently reported hepatic function abnormal, alanine aminotransferase increased, and hepatic enzyme increased. Among the liver neoplasm or nonspecific signs cases, the most frequent PTs were ascites, hepatic cancer, and hepatic cysts (<xref ref-type="table" rid="T3">Table 3</xref>).</p><table-wrap id="T3" orientation="portrait" position="float"><label>TABLE 3</label><caption><p>Distribution of the Preferred Terms (PTs) by DILI cases classified by liver damage origin.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" colspan="1" rowspan="2">Liver damage origin</th><th align="center" colspan="2" rowspan="1">PTs</th></tr><tr><th align="left" colspan="1" rowspan="1">n</th><th align="left" colspan="1" rowspan="1">(%)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">
<bold>Cytolitic</bold>
<xref ref-type="table-fn" rid="Tfn7">
<sup>a</sup>
</xref>
</td><td align="left" colspan="1" rowspan="1">
<bold>97</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>(100)</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hepatic failure</td><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">(21.6)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hepatic cytolysis</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">(8.2)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hepatitis</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">(6.2)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hepatic cirrhosis</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">(5.1)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hepatic lesion</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">(5.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Cholestatic</bold>
<xref ref-type="table-fn" rid="Tfn8">
<sup>b</sup>
</xref>
</td><td align="left" colspan="1" rowspan="1">
<bold>18</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>(100)</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1"> Cholestasis</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">(16.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Jaundice</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">(16.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Jaundice cholestatic</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">(16.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Ocular icterus</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">(5.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Mixed</bold>
<xref ref-type="table-fn" rid="Tfn9">
<sup>c</sup>
</xref>
</td><td align="left" colspan="1" rowspan="1">
<bold>14</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>(100)</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hepatic cytolysis</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">(21.4)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hepatitis cholestatic</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">(21.4)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Jaundice</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">(14.3)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Acute hepatic failure</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">(7.1)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Cholestasis</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">(7.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Not specified</bold>
<xref ref-type="table-fn" rid="Tfn10">
<sup>d</sup>
</xref>
</td><td align="left" colspan="1" rowspan="1">
<bold>61</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>(100)</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1"> Liver disorder</td><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">(34.4)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Drug-induced liver injury</td><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">(21.3)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hepatotoxicity</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">(19.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Liver injury</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">(11.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Liver related investigation</bold>
<xref ref-type="table-fn" rid="Tfn11">
<sup>e</sup>
</xref>
</td><td align="left" colspan="1" rowspan="1">
<bold>176</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>(100)</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hepatic function abnormal</td><td align="left" colspan="1" rowspan="1">41</td><td align="left" colspan="1" rowspan="1">(23.3)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Alanine aminotransferase increased</td><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">(15.3)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hepatic enzyme increased</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">(10.8)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Aspartate aminotransferase increased</td><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">(10.2)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Transaminases increased</td><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">(9.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Liver neoplasm or nonspecific signs</bold>
<xref ref-type="table-fn" rid="Tfn12">
<sup>f</sup>
</xref>
</td><td align="left" colspan="1" rowspan="1">
<bold>73</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>(100)</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1"> Ascites</td><td align="left" colspan="1" rowspan="1">56</td><td align="left" colspan="1" rowspan="1">(76.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hepatic cancer</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">(5.5)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hepatic cyst</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">(5.5)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hepatic cancer recurrent</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">(4.1)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hepatic neoplasm</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">(4.1)</td></tr></tbody></table><table-wrap-foot><fn id="Tfn7"><label>
<sup>a</sup>
</label><p>Cytolytic: ICSRs, reporting at least one PT, belonging to the SMQs “Drug related hepatic disorders–severe events only” (20000007) and suggesting hepatocyte cytolysis.</p></fn><fn id="Tfn8"><label>
<sup>b</sup>
</label><p>Cholestatic: ICSRs, reporting at least one PT, belonging to the SMQs “Cholestasis and jaundice of hepatic origin” (20000009) and suggesting an alteration of the normal flow of bile from the liver to the intestine.</p></fn><fn id="Tfn9"><label>
<sup>c</sup>
</label><p>Mixed: ICSRs, reporting both PTs, of cytolytic origin and PTs, of cholestatic origin.</p></fn><fn id="Tfn10"><label>
<sup>d</sup>
</label><p>Not specified: ICSRs, reporting PTs, not specifically attributable to cytolytic or cholestatic origin (i.e., PTs, belonging to both the SMQs “Drug related hepatic disorders–severe events only” and “Cholestasis and jaundice of hepatic origin”).</p></fn><fn id="Tfn11"><label>
<sup>e</sup>
</label><p>Liver related investigation: ICSRs, reporting only PTs, belonging to the sub-SMQs “Liver related investigations, signs and symptoms” (20000008) or “Liver related coagulation and bleeding disturbances” (20000015).</p></fn><fn id="Tfn12"><label>
<sup>f</sup>
</label><p>Liver neoplasm or nonspecific signs: ICSRs, reporting at least one PT, related to liver neoplasm (benign or malignant) or only PTs, related to nonspecific signs and symptoms.</p></fn><fn><p>Bold values indicate liver damage origin categories; the Preferred Terms (PTs) listed below are classified within these categories.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-3"><label>3.3</label><title>Fatal cases</title><p>Among the 344 DILI cases, there were 23 ICSRs related to fatal AEs, mostly referred to female gender (87.0%), as for the overall. In the majority of ICSRs reporting fatal cases, the age group was not specified (56.5%), while the remaining percentage was equally balanced between the age group 18–64 years and 65–85 years. The primary source country was mostly non-European Economic Area (EEA) (82.6%) and the primary source qualification was mainly represented by HCPs (65.2%), as for the overall DILI cases.</p><p>Most of the fatal cases, were classified as “cytolytic” (52.2%), and as “liver neoplasm or nonspecific signs” (30.4%), as for the overall DILI cases (<xref ref-type="table" rid="T4">Table 4</xref>).</p><table-wrap id="T4" orientation="portrait" position="float"><label>TABLE 4</label><caption><p>Demographic and clinical characteristics of fatal cases.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" colspan="1" rowspan="1">Fatal cases</th><th align="left" colspan="1" rowspan="1">Overall</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">ICSRs n (%)</td><td align="left" colspan="1" rowspan="1">23</td></tr><tr><td align="left" colspan="2" rowspan="1">Age group (%)</td></tr><tr><td align="left" colspan="1" rowspan="1"> 18–64 Years</td><td align="left" colspan="1" rowspan="1">5 (21.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> 65–85 Years</td><td align="left" colspan="1" rowspan="1">5 (21.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Not specified</td><td align="left" colspan="1" rowspan="1">13 (56.5)</td></tr><tr><td align="left" colspan="2" rowspan="1">Sex (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">20 (87.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">3 (13.0)</td></tr><tr><td align="left" colspan="2" rowspan="1">source_qualification (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Healthcare professional</td><td align="left" colspan="1" rowspan="1">15 (65.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Non healthcare professional</td><td align="left" colspan="1" rowspan="1">8 (34.8)</td></tr><tr><td align="left" colspan="2" rowspan="1">source_country (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">European economic area</td><td align="left" colspan="1" rowspan="1">4 (17.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Non european economic area</td><td align="left" colspan="1" rowspan="1">19 (82.6)</td></tr><tr><td align="left" colspan="2" rowspan="1">Liver damage origin (%)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Cytolytic</td><td align="left" colspan="1" rowspan="1">12 (52.2)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Liver neoplasm or nonspecific signs</td><td align="left" colspan="1" rowspan="1">7 (30.4)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Not specified</td><td align="left" colspan="1" rowspan="1">1 (4.3)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Cholestatic</td><td align="left" colspan="1" rowspan="1">2 (8.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Liver related investigation</td><td align="left" colspan="1" rowspan="1">1 (4.3)</td></tr></tbody></table><table-wrap-foot><fn id="Tfn13"><label>
<sup>a</sup>
</label><p>Cytolytic: ICSRs, reporting at least one PT, belonging to the SMQs “Drug related hepatic disorders–severe events only” (20000007) and suggesting hepatocyte cytolysis.</p></fn><fn id="Tfn14"><label>
<sup>b</sup>
</label><p>Cholestatic: ICSRs, reporting at least one PT, belonging to the SMQs “Cholestasis and jaundice of hepatic origin” (20000009) and suggesting an alteration of the normal flow of bile from the liver to the intestine.</p></fn><fn id="Tfn15"><label>
<sup>c</sup>
</label><p>Mixed: ICSRs, reporting both PTs, of cytolytic origin and PTs, of cholestatic origin.</p></fn><fn id="Tfn16"><label>
<sup>d</sup>
</label><p>Not specified: ICSRs, reporting PTs, not specifically attributable to cytolytic or cholestatic origin (i.e., PTs, belonging to both the SMQs “Drug related hepatic disorders–severe events only” and “Cholestasis and jaundice of hepatic origin”).</p></fn><fn id="Tfn17"><label>
<sup>e</sup>
</label><p>Liver related investigation: ICSRs, reporting only PTs, belonging to the sub-SMQs “Liver related investigations, signs and symptoms” (20000008) or “Liver related coagulation and bleeding disturbances” (20000015).</p></fn><fn id="Tfn18"><label>
<sup>f</sup>
</label><p>Liver neoplasm or nonspecific signs: ICSRs, reporting at least one PT, related to liver neoplasm (benign or malignant) or only PTs, related to nonspecific signs and symptoms.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4" sec-type="discussion"><label>4</label><title>Discussion</title><p>Using data from the EV database, we analyzed the safety profile of olaparib in terms of hepatobiliary AEs. This decision derived from a recent question highlighted by the PRAC about the risk of hepatocellular damage associated with this drug (<xref ref-type="bibr" rid="B20">Kim et al., 2015</xref>).</p><p>We found 344 DILI cases, ICSRs reporting at least one narrow PT related to the SMQs “Drug related hepatic disorders–comprehensive search” and olaparib as suspected drug. Patients experiencing olaparib-induced hepatotoxicity were mostly female. The higher female frequency is expected considering that ovarian cancer represents the first therapeutic indication olaparib was approved for, followed by HER2-negative metastatic breast cancer and, only in 2022, its indication was extended for the treatment of metastatic castration-resistant prostate cancer too (<xref ref-type="bibr" rid="B14">Food and Drug Administration, 2024a</xref>; <xref ref-type="bibr" rid="B15">Food and Drug Administration, 2024b</xref>; <xref ref-type="bibr" rid="B16">Food and Drug Administration, 2024c</xref>; <xref ref-type="bibr" rid="B30">Rydberg et al., 2018</xref>). Moreover, it is well known that some gender differences between women and men exist in terms of frequency of experiencing AEs. Women, for instance, tend to experience AEs more commonly than men probably because that sex hormones play in both pharmacokinetics and pharmacodynamics of drugs (<xref ref-type="bibr" rid="B34">Spoletini et al., 2012</xref>). In women menstrual cycle, modifications in the concentration of sexual steroids, the use of oral contraceptives or hormonal substitutive therapy are factors which may influence drug response. On the other hand, the impact of androgens in men is not so relevant thanks to the regular levels of these hormones in blood (<xref ref-type="bibr" rid="B32">Scavone et al., 2020</xref>; <xref ref-type="bibr" rid="B37">Velişcu et al., 2023</xref>; <xref ref-type="bibr" rid="B25">Nicoletti et al., 2023</xref>; <xref ref-type="bibr" rid="B38">Web et al., 2017</xref>).</p><p>We also found that DILI cases related to olaparib occurred more commonly in patients belonging to the age group 18–64 years followed by the age group 65–85 years. This is expected considering that, although ovarian cancer can be diagnosed in women of all ages, its occurrence is quite rare among women aged &lt;40 years considering that the risk increases both with the age and after menopause. Epithelial tumors represent more than 90% above age 40 (<xref ref-type="bibr" rid="B9">Doubeni et al., 2016</xref>; <xref ref-type="bibr" rid="B27">Rahman and Helvie, 2022</xref>). Similarly, in breast cancer pathogenesis, age represents an important risk factor for its occurrence with a median age of new cases between 40 and 49 years. This is generally the age range in which the initiation of screening mammography is recommended (<xref ref-type="bibr" rid="B36">Tufoni et al., 2018</xref>).</p><p>The hepatic-related AEs were mainly classified as serious (above 60%), and 23 ICSRs reported fatal cases. When stratifying DILI cases by liver damage origin, more than 50% referred to cases of cytolytic origin and liver-related investigation. On the other hand, almost 3.5% of DILI cases were classified as of cholestatic origin, \while 1.5% were classified as mixed cases.</p><p>These results are in line with some case reports recently published. The first one describes the case of a 61-year-old woman with BRCA1 mutated ovarian cystadenocarcinoma and no previous history of abnormal liver function. After starting the therapy with olaparib, she has been hospitalized for noticeable hypertransaminasemia (<xref ref-type="bibr" rid="B2">Alshelleh et al., 2022</xref>). Another case report describes the clinical history of a 56-year-old woman with advanced endometrioid and serous carcinoma, firstly treated with neoadjuvant chemotherapy based on carboplatin and paclitaxel. After cancer relapsed, she started retreatment with carboplatin and doxorubicin for a total of 6 cycles. Olaparib was eventually administered because of BRCA1 mutation. Three months after the initiation of olaparib, a severe acute liver injury required the hospitalization of the patient. No use of alcohol was evidenced. Physical examination showed jaundice and no hepatic encephalopathy, while mild hepatomegaly with periportal edema was evidenced by computed tomography (<xref ref-type="bibr" rid="B40">Zhu et al., 2024</xref>). Lastly, Zhu K et al. reported the case of a 70-year-old woman who experienced significant a severe hepatocellular injury after initiating first line maintenance olaparib. Her clinical conditions improved after the culprit drug’s discontinuation but promptly worsened upon rechallenge (<xref ref-type="bibr" rid="B21">Kumachev and Wu, 2021</xref>).</p><p>Most of the fatal cases retrieved by our analysis were classified as “cytolytic” and as “liver neoplasm or nonspecific signs”. In contrast with our results, we found no fatal cases of hepatotoxicity related to olaparib treatment reported in literature. This evidence could suggest that the fatality of these cases may be partially explained by the presence of hepatic neoplasm or the progression of disease.</p><p>Therefore, according to data available from the literature and the results from our study, special attention is required regarding hepatobiliary disorders for olaparib, and further studies are needed to better evaluate the safety profile of the drug. According to the PRAC recommendations, HCPs should constantly monitor the liver function tests during treatment with olaparib. Moreover, in case of potential DILI develops, proper clinical measures should be taken, such as treatment interruption. In case DILI is confirmed, the treatment can be even discontinued.</p><p>Our study has some limitations and strengths. First, we used data from the EV database that, like any other spontaneous reporting system, suffers from the well-known under-reporting phenomena as well as the poor quality and lack of information listed in each ICSR. Indeed, it is known that many ADRs are never reported by healthcare professionals or patients, especially if they are mild or expected. Similarly, ICSRs may contain missing or incomplete or inconsistent clinical information (such as, for example, data related to the outcome that in our study was missing in more than 50% of retrieved ICSRs). For instance, we could not make any analysis concerning the time to onset of olaparib-induced liver injury and similarly we could not exclude the effects deriving from concomitant diseases or medications on the occurrence of DILI. Another important limitation is not knowing whether the reported patients experiencing “liver neoplasm or non-specific signs” have had liver metastases before starting treatment with olaparib. Thus, the overall results should be interpreted with caution. In addition, as any data based on the spontaneous reporting system, our data lack of denominator data and thus we do not know how many people actually used the drug, at what dose, or for how long. Therefore, incidence rates cannot be calculated. What’s more, we could not establish causality considering that EV is designed to detect signals, not to prove that a drug causes an event and we cannot rule out that many events could be related with the illness rather than the drug (leading to a confounding by indication). Lastly, since we classified retrieved cases according to the PT reported, the possibility of a misclassification bias (the wrong classification of cases, placed into the wrong categories, cytolytic or cholestatic) cannot be rules out. Considering these limitations, we are aware that the real hepatic safety profile of olaparib cannot be fully established but needs to be confirmed by the results obtained from <italic toggle="yes">ad hoc</italic> studies. On the other hand, we carried out a descriptive analysis of data derived from the EV database to identify cases of liver injury related to olaparib and to classify these cases according to their liver damage origin. A team of pharmacologists and clinicians with consolidated experience in pharmacovigilance performed this classification, with the aim to guarantee high quality standard for the overall methodological process. In addition, despite its limitations, the spontaneous reporting system represents a useful and inexpensive tool for the collection and analysis of medicine safety data for population excluded from premarketing clinical studies and for the identification of ADRs that are not detectable during the pre-marketing phase.</p></sec><sec id="s5" sec-type="conclusion"><label>5</label><title>Conclusion</title><p>We found out that most DILI cases occurred in female patients belonging to the age group 18–64 years. DILI cases mainly were represented by cases of cytolytic origins and cases associated with liver related investigation. There were 23 fatal cases, mostly classified as “cytolytic” and “liver neoplasm or nonspecific signs”.</p><p>Additional pharmacovigilance studies assessing the hepatic safety profile of olaparib is required in light of the findings obtained from the EV. In addition, evaluation of the pathophysiological mechanism underlying the drug-induced liver damage could provide clinicians with practical resources for prevention and treatment.</p></sec></body><back><fn-group><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1048838/overview" xmlns:xlink="http://www.w3.org/1999/xlink">Salvatore Crisafulli</ext-link>, University of Verona, Italy</p></fn><fn fn-type="reviewed-by"><p>
<bold>Reviewed by:</bold>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/523258/overview" xmlns:xlink="http://www.w3.org/1999/xlink">Irma Convertino</ext-link>, University of Pisa, Italy</p><p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3277655/overview" xmlns:xlink="http://www.w3.org/1999/xlink">Héctor Carlos García Díaz</ext-link>, Vall d'Hebron University Hospital, Spain</p></fn></fn-group><sec id="s6" sec-type="data-availability"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec id="s7" sec-type="author-contributions"><title>Author contributions</title><p>E-MV: Investigation, Data curation, Methodology, Writing – original draft, Formal Analysis. CC: Investigation, Methodology, Data curation, Formal Analysis, Writing – original draft. MS: Investigation, Formal Analysis, Conceptualization, Writing – review and editing, Methodology. AA: Writing – original draft, Investigation, Formal Analysis, Data curation. FS: Supervision, Writing – review and editing, Methodology, Conceptualization, Project administration, Visualization, Validation. CS: Writing – review and editing, Conceptualization, Supervision, Project administration, Validation, Methodology, Visualization.</p></sec><sec id="s9" sec-type="COI-statement"><title>Conflict of interest</title><p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec id="s10" sec-type="ai-statement"><title>Generative AI statement</title><p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec id="s11" sec-type="disclaimer"><title>Publisher’s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec id="s12" sec-type="supplementary-material"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fdsfr.2025.1736759/full#supplementary-material" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.frontiersin.org/articles/10.3389/fdsfr.2025.1736759/full#supplementary-material</ext-link>
</p><supplementary-material content-type="local-data" id="SM1" orientation="portrait" position="float"><media orientation="portrait" position="float" xlink:href="Table1.docx" xmlns:xlink="http://www.w3.org/1999/xlink"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Aithal</surname><given-names>G. P.</given-names></name>
<name name-style="western"><surname>Watkins</surname><given-names>P. B.</given-names></name>
<name name-style="western"><surname>Andrade</surname><given-names>R. J.</given-names></name>
<name name-style="western"><surname>Larrey</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Molokhia</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Takikawa</surname><given-names>H.</given-names></name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Case definition and phenotype standardization in drug-induced liver injury</article-title>. <source>Clin. Pharmacology Therapeutics</source>
<volume>89</volume> (<issue>6</issue>), <fpage>806</fpage>–<lpage>815</lpage>. <pub-id pub-id-type="doi">10.1038/clpt.2011.58</pub-id>
<pub-id pub-id-type="pmid">21544079</pub-id>
</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Alshelleh</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Park</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>John</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Rishi</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Bernstein</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Roth</surname><given-names>N.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Olaparib-induced immune-mediated liver injury</article-title>. <source>ACG Case Reports Journal</source>
<volume>9</volume> (<issue>1</issue>), <fpage>e00735</fpage>. <pub-id pub-id-type="doi">10.14309/crj.0000000000000735</pub-id>
<pub-id pub-id-type="pmid">35028326</pub-id>
<pub-id pub-id-type="pmcid">PMC8751767</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Banerjee</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Moore</surname><given-names>K. N.</given-names></name>
<name name-style="western"><surname>Colombo</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Scambia</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>B.-G.</given-names></name>
<name name-style="western"><surname>Oaknin</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial</article-title>. <source>Lancet Oncol.</source>
<volume>22</volume> (<issue>12</issue>), <fpage>1721</fpage>–<lpage>1731</lpage>. <pub-id pub-id-type="doi">10.1016/s1470-2045(21)00531-3</pub-id>
<pub-id pub-id-type="pmid">34715071</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Björnsson</surname><given-names>H. K.</given-names></name>
<name name-style="western"><surname>Björnsson</surname><given-names>E. S.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Drug-induced liver injury: pathogenesis, epidemiology, clinical features, and practical management</article-title>. <source>Eur. Journal Internal Medicine</source>
<volume>97</volume>, <fpage>26</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejim.2021.10.035</pub-id>
<pub-id pub-id-type="pmid">34772600</pub-id>
</mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Bochum</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Berger</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Martens</surname><given-names>U. M.</given-names></name>
</person-group> (<year>2018</year>). <article-title>Olaparib</article-title>. <source>Recent Results Cancer Research.</source>
<volume>211</volume>, <fpage>217</fpage>–<lpage>233</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-319-91442-8_15</pub-id>
<pub-id pub-id-type="pmid">30069770</pub-id>
</mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Boussios</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Rassy</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Moschetta</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Ghose</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Adeleke</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Sanchez</surname><given-names>E.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>BRCA mutations in ovarian and prostate cancer: bench to bedside</article-title>. <source>Cancers</source>
<volume>14</volume> (<issue>16</issue>), <fpage>3888</fpage>. <pub-id pub-id-type="doi">10.3390/cancers14163888</pub-id>
<pub-id pub-id-type="pmid">36010882</pub-id>
<pub-id pub-id-type="pmcid">PMC9405840</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Brown</surname><given-names>E. G.</given-names></name>
</person-group> (<year>2003</year>). <article-title>Methods and pitfalls in searching drug safety databases utilising the medical dictionary for regulatory activities (MedDRA)</article-title>. <source>Drug Saf.</source>
<volume>26</volume>, <fpage>145</fpage>–<lpage>158</lpage>. <pub-id pub-id-type="doi">10.2165/00002018-200326030-00002</pub-id>
<pub-id pub-id-type="pmid">12580645</pub-id>
</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>DiSilvestro</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Banerjee</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Colombo</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Scambia</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>B. G.</given-names></name>
<name name-style="western"><surname>Oaknin</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Overall survival with maintenance olaparib at a 7-Year Follow-Up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial</article-title>. <source>J. Clinical Oncology</source>
<volume>41</volume> (<issue>3</issue>), <fpage>609</fpage>–<lpage>617</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.22.01549</pub-id>
<pub-id pub-id-type="pmid">36082969</pub-id>
<pub-id pub-id-type="pmcid">PMC9870219</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Doubeni</surname><given-names>C. A.</given-names></name>
<name name-style="western"><surname>Doubeni</surname><given-names>A. R.</given-names></name>
<name name-style="western"><surname>Myers</surname><given-names>A. E.</given-names></name>
</person-group> (<year>2016</year>). <article-title>Diagnosis and management of ovarian cancer</article-title>. <source>Am. Family Physician</source>
<volume>93</volume> (<issue>11</issue>), <fpage>937</fpage>–<lpage>944</lpage>.
<pub-id pub-id-type="pmid">27281838</pub-id>
</mixed-citation></ref><ref id="B10"><mixed-citation publication-type="webpage">
<collab>EMA</collab> (<year>2023</year>). <article-title>ICH topic E 2 A clinical safety data management: definitions and standards for expedited reporting</article-title>. <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf</ext-link> (accessed on November 7, 2023)</comment>.</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="webpage">
<collab>European Medicines Agency</collab> (<year>2024</year>). <article-title>Serious adverse reaction</article-title>. <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/glossary/serious-adverse-reaction" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.ema.europa.eu/en/glossary/serious-adverse-reaction</ext-link> (Accessed April 30, 2024)</comment>.</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="webpage">
<collab>European Medicines Agency</collab> (<year>2025</year>). <article-title>PRAC recommendations on signals</article-title>. <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_en.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-3-6-july-2023-prac-meeting_en.pdf</ext-link> (accessed on: January 29, 2025)</comment>.</mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Fallah</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Weinstock</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Brave</surname><given-names>M. H.</given-names></name>
<name name-style="western"><surname>Bloomquist</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Fiero</surname><given-names>M. H.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>FDA approval summary: olaparib in combination with abiraterone for treatment of patients with <italic toggle="yes">BRCA</italic>-mutated metastatic castration-resistant prostate cancer</article-title>. <source>J. Clinical Oncology</source>
<volume>42</volume> (<issue>5</issue>), <fpage>605</fpage>–<lpage>613</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.23.01868</pub-id>
<pub-id pub-id-type="pmid">38127780</pub-id>
</mixed-citation></ref><ref id="B14"><mixed-citation publication-type="webpage">
<collab>Food and Drug Administration</collab> (<year>2024a</year>). <article-title>FDA approves olaparib tablets for maintenance treatment in ovarian cancer</article-title>. <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-tablets-maintenance-treatment-ovarian-cancer" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-tablets-maintenance-treatment-ovarian-cancer</ext-link> (Accessed January 16, 2024)</comment>.</mixed-citation></ref><ref id="B15"><mixed-citation publication-type="webpage">
<collab>Food and Drug Administration</collab> (<year>2024b</year>). <article-title>FDA approves olaparib for germline BRCA-Mutated metastatic breast cancer</article-title>. <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-germline-brca-mutated-metastatic-breast-cancer" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-germline-brca-mutated-metastatic-breast-cancer</ext-link> (Accessed January 29, 2024)</comment>.</mixed-citation></ref><ref id="B16"><mixed-citation publication-type="webpage">
<collab>Food and Drug Administration</collab> (<year>2024c</year>). <article-title>FDA approves olaparib for gBRCAm metastatic pancreatic adenocarcinoma</article-title>. <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-gbrcam-metastatic-pancreatic-adenocarcinoma" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-gbrcam-metastatic-pancreatic-adenocarcinoma</ext-link> (Accessed January 29, 2024)</comment>.</mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Garcia-Cortes</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Robles-Diaz</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Stephens</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Ortega-Alonso</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Lucena</surname><given-names>M. I.</given-names></name>
<name name-style="western"><surname>Andrade</surname><given-names>R. J.</given-names></name>
</person-group> (<year>2020</year>). <article-title>Drug induced liver injury: an update</article-title>. <source>Arch. Toxicol.</source>
<volume>94</volume>, <fpage>3381</fpage>–<lpage>3407</lpage>. <pub-id pub-id-type="doi">10.1007/s00204-020-02885-1</pub-id>
<pub-id pub-id-type="pmid">32852569</pub-id>
</mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Golan</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Hammel</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Reni</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Van Cutsem</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Macarulla</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Hall</surname><given-names>M. J.</given-names></name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Maintenance olaparib for germline <italic toggle="yes">BRCA</italic>-mutated metastatic pancreatic cancer</article-title>. <source>N. Engl. Journal Medicine</source>
<volume>381</volume> (<issue>4</issue>), <fpage>317</fpage>–<lpage>327</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1903387</pub-id>
<pub-id pub-id-type="pmid">31157963</pub-id>
<pub-id pub-id-type="pmcid">PMC6810605</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Guo</surname><given-names>X. X.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>H. L.</given-names></name>
<name name-style="western"><surname>Shi</surname><given-names>H. Y.</given-names></name>
<name name-style="western"><surname>Su</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>
</person-group> (<year>2018</year>). <article-title>The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials</article-title>. <source>Cancer Manag. Res.</source>
<volume>10</volume>, <fpage>2553</fpage>–<lpage>2562</lpage>. <pub-id pub-id-type="doi">10.2147/CMAR.S169558</pub-id>
<pub-id pub-id-type="pmid">30127642</pub-id>
<pub-id pub-id-type="pmcid">PMC6089112</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Kim</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Ison</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>McKee</surname><given-names>A. E.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Tang</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Gwise</surname><given-names>T.</given-names></name>
<etal/>
</person-group> (<year>2015</year>). <article-title>FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy</article-title>. <source>Clin. Cancer Research An Official Journal Am. Assoc. Cancer Res.</source>
<volume>21</volume> (<issue>19</issue>), <fpage>4257</fpage>–<lpage>4261</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-0887</pub-id>
<pub-id pub-id-type="pmid">26187614</pub-id>
</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Kumachev</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>P. E.</given-names></name>
</person-group> (<year>2021</year>). <article-title>Drug-induced liver injury</article-title>. <source>CMAJ</source>
<volume>193</volume> (<issue>9</issue>), <fpage>E310</fpage>. <pub-id pub-id-type="doi">10.1503/cmaj.202026</pub-id>
<pub-id pub-id-type="pmid">33649170</pub-id>
<pub-id pub-id-type="pmcid">PMC8034304</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Luo</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Lu</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Xiang</surname><given-names>Z.</given-names></name>
</person-group> (<year>2017</year>). <article-title>A review of drug-induced liver injury databases</article-title>. <source>Archives Toxicol.</source>
<volume>91</volume>, <fpage>3039</fpage>–<lpage>3049</lpage>. <pub-id pub-id-type="doi">10.1007/s00204-017-2024-8</pub-id>
<pub-id pub-id-type="pmid">28717830</pub-id>
</mixed-citation></ref><ref id="B23"><mixed-citation publication-type="webpage">
<collab>Meddra</collab> (<year>2025</year>). <article-title>Introductory guide for standardised MedDRA queries (SMQs)</article-title>. <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://admin.meddra.org/sites/default/files/guidance/file/SMQ_intguide_25_1_English.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">https://admin.meddra.org/sites/default/files/guidance/file/SMQ_intguide_25_1_English.pdf</ext-link>.</comment>
</mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Mozzicato</surname><given-names>P.</given-names></name>
</person-group> (<year>2007</year>). <article-title>Standardised MedDRA queries: their role in signal detection</article-title>. <source>Drug Saf.</source>
<volume>30</volume> (<issue>7</issue>), <fpage>617</fpage>–<lpage>619</lpage>. <pub-id pub-id-type="doi">10.2165/00002018-200730070-00009</pub-id>
<pub-id pub-id-type="pmid">17604415</pub-id>
</mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Nicoletti</surname><given-names>M. M.</given-names></name>
<name name-style="western"><surname>Anatriello</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Liguori</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Cantone</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>di Mauro</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Izzo</surname><given-names>I.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Skin toxicities associated with botulin toxin injection for aesthetic procedures: data from the European spontaneous reporting system</article-title>. <source>Pharm. Basel, Switz.</source>
<volume>16</volume> (<issue>11</issue>), <fpage>1611</fpage>. <pub-id pub-id-type="doi">10.3390/ph16111611</pub-id>
<pub-id pub-id-type="pmid">38004476</pub-id>
<pub-id pub-id-type="pmcid">PMC10675122</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="webpage">
<collab>Niraparib</collab> (<year>2017</year>). <article-title>Nih.gov; national institute of diabetes and digestive and kidney diseases</article-title>. <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK548333/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.ncbi.nlm.nih.gov/books/NBK548333/</ext-link>.</comment>
</mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Rahman</surname><given-names>W. T.</given-names></name>
<name name-style="western"><surname>Helvie</surname><given-names>M. A.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Breast cancer screening in average and high-risk women. Best practice &amp; research</article-title>. <source>Clin. Obstetrics &amp; Gynaecology</source>
<volume>83</volume>, <fpage>3</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpobgyn.2021.11.007</pub-id>
<pub-id pub-id-type="pmid">34903436</pub-id>
</mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Robson</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Im</surname><given-names>S. A.</given-names></name>
<name name-style="western"><surname>Senkus</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Domchek</surname><given-names>S. M.</given-names></name>
<name name-style="western"><surname>Masuda</surname><given-names>N.</given-names></name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Olaparib for metastatic breast cancer in patients with a germline BRCA mutation</article-title>. <source>N. Engl. Journal Medicine</source>
<volume>377</volume> (<issue>6</issue>), <fpage>523</fpage>–<lpage>533</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1706450</pub-id>
<pub-id pub-id-type="pmid">28578601</pub-id>
</mixed-citation></ref><ref id="B29"><mixed-citation publication-type="webpage">
<collab>Rucaparib</collab> (<year>2017</year>). <article-title>Nih.gov; national institute of diabetes and digestive and kidney diseases</article-title>. <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK548767/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.ncbi.nlm.nih.gov/books/NBK548767/</ext-link>.</comment>
</mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Rydberg</surname><given-names>D. M.</given-names></name>
<name name-style="western"><surname>Mejyr</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Loikas</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Schenck-Gustafsson</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>von Euler</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Malmström</surname><given-names>R. E.</given-names></name>
</person-group> (<year>2018</year>). <article-title>Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs</article-title>. <source>Eur. Journal Clinical Pharmacology</source>
<volume>74</volume> (<issue>9</issue>), <fpage>1165</fpage>–<lpage>1173</lpage>. <pub-id pub-id-type="doi">10.1007/s00228-018-2480-y</pub-id>
<pub-id pub-id-type="pmid">29804162</pub-id>
<pub-id pub-id-type="pmcid">PMC6096710</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Sakaeda</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Tamon</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Kadoyama</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Okuno</surname><given-names>Y.</given-names></name>
</person-group> (<year>2013</year>). <article-title>Data mining of the public version of the FDA adverse event reporting system</article-title>. <source>Int. J. Med. Sci.</source>
<volume>10</volume>, <fpage>796</fpage>–<lpage>803</lpage>. <pub-id pub-id-type="doi">10.7150/ijms.6048</pub-id>
<pub-id pub-id-type="pmid">23794943</pub-id>
<pub-id pub-id-type="pmcid">PMC3689877</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Scavone</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Di Mauro</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Ruggiero</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Bernardi</surname><given-names>F. F.</given-names></name>
<name name-style="western"><surname>Trama</surname><given-names>U.</given-names></name>
<name name-style="western"><surname>Aiezza</surname><given-names>M. L.</given-names></name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Severe cutaneous adverse drug reactions associated with allopurinol: an analysis of spontaneous reporting system in southern Italy</article-title>. <source>Drugs - Real World Outcomes</source>
<volume>7</volume> (<issue>1</issue>), <fpage>41</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1007/s40801-019-00174-7</pub-id>
<pub-id pub-id-type="pmid">31848905</pub-id>
<pub-id pub-id-type="pmcid">PMC7060978</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Sow</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Doumbia</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Moussa</surname><given-names>Y. D.</given-names></name>
<name name-style="western"><surname>Sanogo</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Makan</surname><given-names>S. T.</given-names></name>
<name name-style="western"><surname>Diarra</surname><given-names>O.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Etiologies of liver cytolysis in the service of hepato-gastroenterology of the gabriel toure university hospital</article-title>. <source>Open J. Gastroenterology</source>
<volume>11</volume> (<issue>11</issue>), <fpage>211</fpage>–<lpage>219</lpage>. <pub-id pub-id-type="doi">10.4236/ojgas.2021.1111022</pub-id>
</mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Spoletini</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Vitale</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Malorni</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Rosano</surname><given-names>G. M.</given-names></name>
</person-group> (<year>2012</year>). <article-title>Sex differences in drug effects: interaction with sex hormones in adult life</article-title>. <source>Handb. Experimental Pharmacology</source> (<issue>214</issue>), <fpage>91</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-642-30726-3_5</pub-id>
<pub-id pub-id-type="pmid">23027447</pub-id>
</mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Tobalina</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Armenia</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Irving</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>O'Connor</surname><given-names>M. J.</given-names></name>
<name name-style="western"><surname>Forment</surname><given-names>J. V.</given-names></name>
</person-group> (<year>2021</year>). <article-title>A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance</article-title>. <source>Ann. Oncology Official Journal Eur. Soc. Med. Oncol.</source>
<volume>32</volume> (<issue>1</issue>), <fpage>103</fpage>–<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1016/j.annonc.2020.10.470</pub-id>
<pub-id pub-id-type="pmid">33091561</pub-id>
</mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Tufoni</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Serena Ricci</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Zaccherini</surname><given-names>G.</given-names></name>
</person-group> (<year>2018</year>). <article-title>A case of immune-mediated liver injury induced by olaparib</article-title>. <source>Hepatol. Baltim. Md</source>
<volume>68</volume> (<issue>5</issue>), <fpage>2039</fpage>–<lpage>2041</lpage>. <pub-id pub-id-type="doi">10.1002/hep.30119</pub-id>
<pub-id pub-id-type="pmid">30070367</pub-id>
</mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Velişcu</surname><given-names>E. M.</given-names></name>
<name name-style="western"><surname>Liguori</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Anatriello</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Maniscalco</surname><given-names>G. T.</given-names></name>
<name name-style="western"><surname>Cantone</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Di Costanzo</surname><given-names>L.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Hepatobiliary adverse reactions during treatment with cladribine: analysis of data from the European spontaneous reporting system</article-title>. <source>Pharmaceuticals</source>
<volume>16</volume>, <fpage>1071</fpage>. <pub-id pub-id-type="doi">10.3390/ph16081071</pub-id>
<pub-id pub-id-type="pmid">37630986</pub-id>
<pub-id pub-id-type="pmcid">PMC10459297</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Webb</surname><given-names>P. M.</given-names></name>
<name name-style="western"><surname>Jordan</surname><given-names>S. J.</given-names></name>
</person-group> (<year>2017</year>). <article-title>Epidemiology of epithelial ovarian cancer. Best practice &amp; research</article-title>. <source>Clin. Obstetrics &amp; Gynaecology</source>
<volume>41</volume>, <fpage>3</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpobgyn.2016.08.006</pub-id>
<pub-id pub-id-type="pmid">27743768</pub-id>
</mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Yang</surname><given-names>X. D.</given-names></name>
<name name-style="western"><surname>Kong</surname><given-names>F. E.</given-names></name>
<name name-style="western"><surname>Qi</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Lin</surname><given-names>J. X.</given-names></name>
<name name-style="western"><surname>Yan</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Loong</surname><given-names>J. H. C.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>PARP inhibitor olaparib overcomes sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma</article-title>. <source>Mol. Cancer</source>
<volume>20</volume> (<issue>1</issue>), <fpage>20</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-021-01315-9</pub-id>
<pub-id pub-id-type="pmid">33485358</pub-id>
<pub-id pub-id-type="pmcid">PMC7824946</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zhu</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Drew</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Jayakumar</surname><given-names>S.</given-names></name>
</person-group> (<year>2024</year>). <article-title>Challenges in PARP inhibitor therapy: a case of olaparib-induced liver injury and successful rechallenge with niraparib</article-title>. <source>Gynecol. Oncol. Rep.</source>
<volume>54</volume>, <fpage>101439</fpage>. <pub-id pub-id-type="doi">10.1016/j.gore.2024.101439</pub-id>
<pub-id pub-id-type="pmid">39035031</pub-id>
<pub-id pub-id-type="pmcid">PMC11259776</pub-id></mixed-citation></ref></ref-list></back></article>